Other · developed by Evaxion Biotech
EVX-02B is an investigational agent administered intramuscularly.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04455503 | Phase 1/2 | Melanoma Stage IV | Terminated | EVAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Melanoma Stage IIIMelanoma Stage IV
Updated Nov 15, 2026. Something wrong or missing? Report it on the EVAX page.
See EVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EVAX catalysts and pipeline →